uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 2,916 Shares

uniQure (NASDAQ:QURE) CFO Christian Klemt sold 2,916 shares of uniQure stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the transaction, the chief financial officer now directly owns 155,168 shares in the company, valued at approximately $1,756,501.76. This trade represents a 1.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Christian Klemt also recently made the following trade(s):

• On Tuesday, February 25th, Christian Klemt sold 14,341 shares of uniQure stock. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70.
• On Monday, December 9th, Christian Klemt sold 1,796 shares of uniQure stock. The stock was sold at an average price of $7.55, for a total transaction of $13,559.80.

uniQure Stock Performance

uniQure stock opened at $12.07 on Friday. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market cap of $588.33 million, a P/E ratio of -2.43 and a beta of 0.38. The stock has a 50 day moving average of $15.12 and a 200-day moving average of $9.75.

Wall Street Analysts Forecast Growth

Several research analysts have commented on QURE shares. Guggenheim reissued a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and boosted their price target for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. Leerink Partners lifted their price objective on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. Finally, StockNews.com upgraded shares of uniQure to a “sell” rating in a research note on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $40.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in QURE. Twin Tree Management LP bought a new stake in shares of uniQure in the 4th quarter worth about $77,000. FNY Investment Advisers LLC acquired a new position in uniQure in the fourth quarter worth about $88,000. RTW Investments LP bought a new stake in uniQure in the third quarter valued at about $49,000. ADAR1 Capital Management LLC acquired a new stake in uniQure during the fourth quarter valued at approximately $177,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 3,663 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.